These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 18687302

  • 1. Cancer immunotherapeutic effects of novel CpG ODN in murine tumor model.
    Cho HC, Kim BH, Kim K, Park JY, Chang JH, Kim SK.
    Int Immunopharmacol; 2008 Oct; 8(10):1401-7. PubMed ID: 18687302
    [Abstract] [Full Text] [Related]

  • 2. Screening of novel immunostimulatory CpG ODNs and their anti-leukemic effects as immunoadjuvants of tumor vaccines in murine acute lymphoblastic leukemia.
    Wang J, Zhang W, He A, Zhao W, Cao X.
    Oncol Rep; 2011 Feb; 25(2):519-29. PubMed ID: 21165566
    [Abstract] [Full Text] [Related]

  • 3. CpG-ODN-based immunotherapy is effective in controlling the growth of metastasized tumor cells.
    Kim HA, Ko HM, Ju HW, Kim KJ, Roh SG, Lee HK, Im SY.
    Cancer Lett; 2009 Feb 08; 274(1):160-4. PubMed ID: 18952369
    [Abstract] [Full Text] [Related]

  • 4. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA.
    Ballas ZK, Rasmussen WL, Krieg AM.
    J Immunol; 1996 Sep 01; 157(5):1840-5. PubMed ID: 8757300
    [Abstract] [Full Text] [Related]

  • 5. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
    Olbert PJ, Schrader AJ, Simon C, Dalpke A, Barth P, Hofmann R, Hegele A.
    Anticancer Res; 2009 Jun 01; 29(6):2067-76. PubMed ID: 19528466
    [Abstract] [Full Text] [Related]

  • 6. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
    Wakita D, Chamoto K, Zhang Y, Narita Y, Noguchi D, Ohnishi H, Iguchi T, Sakai T, Ikeda H, Nishimura T.
    Int Immunol; 2006 Mar 01; 18(3):425-34. PubMed ID: 16415100
    [Abstract] [Full Text] [Related]

  • 7. Antimetastatic effect of CpG DNA mediated by type I IFN.
    Hafner M, Zawatzky R, Hirtreiter C, Buurman WA, Echtenacher B, Hehlgans T, Männel DN.
    Cancer Res; 2001 Jul 15; 61(14):5523-8. PubMed ID: 11454702
    [Abstract] [Full Text] [Related]

  • 8. CpG oligodeoxynucleotide-induced immunity prevents growth of germinal center-derived B lymphoma cells.
    Ponzio NM, Cutro S, Hu J, Marzouk A, Marshall JD.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):2057-68. PubMed ID: 17161362
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effective CpG immunotherapy of breast carcinoma prevents but fails to eradicate established brain metastasis.
    Xiong Z, Gharagozlou S, Vengco I, Chen W, Ohlfest JR.
    Clin Cancer Res; 2008 Sep 01; 14(17):5484-93. PubMed ID: 18765540
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Role of invariant NK T lymphocytes in immune responses to CpG oligodeoxynucleotides.
    Paget C, Bialecki E, Fontaine J, Vendeville C, Mallevaey T, Faveeuw C, Trottein F.
    J Immunol; 2009 Feb 15; 182(4):1846-53. PubMed ID: 19201836
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model.
    Liu LL, Smith MJ, Sun BS, Wang GJ, Redmond HP, Wang JH.
    Ann Surg Oncol; 2009 May 15; 16(5):1403-11. PubMed ID: 19263173
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Interleukin-4 and CpG oligonucleotide therapy suppresses the outgrowth of tumors by activating tumor-specific Th1-type immune responses.
    Kajiwara A, Doi H, Eguchi J, Ishii S, Hiraide-Sasagawa A, Sakaki M, Omori R, Hiroishi K, Imawari M.
    Oncol Rep; 2012 Jun 15; 27(6):1765-71. PubMed ID: 22426807
    [Abstract] [Full Text] [Related]

  • 17. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
    Ren T, Wen ZK, Liu ZM, Qian C, Liang YJ, Jin ML, Cai YY, Xu L.
    Cancer Invest; 2008 Jun 15; 26(5):448-55. PubMed ID: 18568766
    [Abstract] [Full Text] [Related]

  • 18. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
    van Ojik HH, Bevaart L, Dahle CE, Bakker A, Jansen MJ, van Vugt MJ, van de Winkel JG, Weiner GJ.
    Cancer Res; 2003 Sep 01; 63(17):5595-600. PubMed ID: 14500400
    [Abstract] [Full Text] [Related]

  • 19. Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells.
    Sabel MS, Arora A, Su G, Mathiowitz E, Reineke JJ, Chang AE.
    Surgery; 2007 Nov 01; 142(5):749-60. PubMed ID: 17981196
    [Abstract] [Full Text] [Related]

  • 20. Interleukin-28B acts synergistically with cisplatin to suppress the growth of head and neck squamous cell carcinoma.
    Yoshimoto K, Kishida T, Nakano H, Matsui M, Shin-Ya M, Shimada T, Nakai S, Imanishi J, Takeuchi M, Hisa Y, Mazda O.
    J Immunother; 2011 Mar 01; 34(2):139-48. PubMed ID: 21304406
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.